Gastón Lucas Martinengo
22 works · 5,192 citations · h-index 10
Top works
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
- Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
- KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
- Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina
- OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
- LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
- Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).
- A Time and Motion Study Comparing Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab in Combination with Chemotherapy for the Treatment of Metastatic Non-small Cell Lung Cancer
- LBA67 Perioperative pembrolizumab in early-stage non-small- cell lung cancer (NSCLC): 5-year follow-up from KEYNOTE- 671
- Model-based dose selection and pharmacokinetic bridging of subcutaneous from intravenous pembrolizumab across indications
- 223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC
- Safety and Effectiveness of Brigatinib in Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Post-Marketing Surveillance Study
- P1.01-058 Real World Data with Nivolumab: Experience in Argentina
- P1.11.85 Overall Survival With Nivolumab Plus Relatlimab With Platinum-Doublet Chemotherapy in Metastatic NSCLC From RELATIVITY-104
- LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
- Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
- Trayectoria de Pacientes, Patrones de Tratamiento y Utilización de Recursos Sanitarios en Estadios Tempranos de NSCLC en Argentina